Page 72 - 2021_02-Haematologica-web

P. Robach et al.
A
B
C
D
Figure 2. Effects of repeated administration of very low to low doses of recombinant human erythropoietin on hematologic and iron parameters. (A-D) Blood hemo- globin concentration (A), hematocrit (B), serum concentration of ferritin (ln transformed) (C) and transferrin saturation (D) before, during and after six injections of placebo (n=8), recombinant human erythropoietin (rhEpo) 20 IU/kg (micro-dose) (n=8) or rhEpo 50 IU/kg (low dose) (n=8). Vertical dotted lines indicate injections. Baselines are means from duplicate blood samples collected on separated days. Blood sampling was repeatedly performed at 24 h (2 occurrences), 48 h (4 occur- rences) and 72 h (2 occurrences) after an injection. Additional samples were obtained at 7 and 14 days after the last injection. Numbers above the abscissa line (i.e., 24, 48, 72, 7d and 14d) indicate these sampling times. Data are means ± standard deviations. For each panel, the inserted table reports estimated marginal means ± standard errors and P-values for the effect of the group (placebo, micro-dose, low dose), the occurrence (i.e., the number of samples at 24 h, 48 h, 72 h, 7 days and 14 days, from 1 to 4) and the group × occurrence (G × O) interaction. Multiple comparisons between groups at 24 h, 48 h or 72 h are reported in each table, *Denotes a difference from placebo and ‡denotes a difference from micro-dose (see the Online Supplementary Material, Statistical analysis section). Epo: erythropoietin; ERFE: erythroferrone; PLA: placebo. EPO20: recombinant human erythropoietin 20 IU/kg; EPO50: recombinant human erythropoietin 50 IU/kg.
386
haematologica | 2021; 106(2)